Osteocytic SOCS3 controls STAT3:STAT1 balance and bone formation

骨细胞 SOCS3 控制 STAT3:STAT1 平衡和骨形成

• 批准号: nhmrc : 1058625
• 负责人: A/Pr Natalie Sims
• 金额: $ 43.22万
• 依托单位: St. Vincent's Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/osteocytic-socs3-controls-bone-formation/454691
• 关键词: Osteocytic; SOCS3; controls; STAT3; STAT1

The most promising new osteoporosis therapy is antibody-based inhibition of the sclerostin protein. We discovered that sclerostin is inhibited by oncostatin M (OSM) only when it binds to a receptor called LIFR, which then activates proteins STAT3 and SOCS3. If OSM binds a different receptor (OSMR) it increases STAT1 activity and destroys bone. This project will determine how to manipulate STAT3, SOCS3, and STAT1 to increase bone formation and provide new treatments for osteoporosis.

最有前途的新的骨质疏松症治疗是基于抗体的sclerostin蛋白的抑制。我们发现sclerostin只有在与一种名为LIFR的受体结合时才能被制瘤素M（OSM）抑制，LIFR然后激活蛋白质STAT3和SOCS3。如果OSM结合不同的受体（OSMR），它会增加STAT1的活性并破坏骨骼。该项目将确定如何操纵STAT3，SOCS3和STAT1以增加骨形成并为骨质疏松症提供新的治疗方法。